[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.189.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 485
Citations 0
News From the Food and Drug Administration
September 6, 2016

Relief From Dry Eye Disease

JAMA. 2016;316(9):918. doi:10.1001/jama.2016.11454

Lifitegrast ophthalmic solution is the first in a new class of drugs called lymphocyte function–associated antigen 1 (LFA-1) antagonists to receive FDA approval for treating the signs and symptoms of dry eye disease in adults.

Marketed as Xiidra, the drug was evaluated in more than 1000 patients in 4 trials. Patients were randomized to receive the LFA-1 antagonist or placebo eye drops, used twice daily for 12 weeks. Trial participants were aged 19 to 97 years and 76% were female. The findings showed that patients who received the LFA-1 antagonist had greater improvement in both the signs and symptoms of eye dryness compared with patients in the placebo group (http://bit.ly/29toDTi).

First Page Preview View Large
First page PDF preview
First page PDF preview
×